Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

Abstract: Disclosed are an automatic remote water supply system in a low gravity environment, which includes a water supply unit, an environment detection unit and a control unit. The water supply unit includes a water bag, an air inlet pipe, a water pipe and a water pump on the water pipe. The bottom of the water bag has an air inlet and a water outlet. The air inlet pipe is communicated with the water bag through the air inlet. The water pipe is communicated with the water bag through the water outlet. The environment detection unit is configured to detect environmental information in the ecosystem to which the water supply system belongs in the low gravity environment. The control unit is configured to control the starting state of the water pump according to the environmental information, so that water in the water bag flows out through the water pipe.

Abstract: A display substrate includes a base substrate including a display region and a frame region, multiple pixel circuits, first light-emitting elements and at least one first data line, located in a first sub-display region, multiple second light-emitting elements located in a second sub-display region. The display region includes a foldable first display region and second display region each including a first sub-display region and second sub-display region; multiple pixel circuits includes multiple first pixel circuits and second pixel circuits distributed among multiple first pixel circuits; at least one first pixel circuits is connected with at least one of multiple-first light-emitting elements; at least one of multiple second pixel circuits is connected with at least one of multiple second light-emitting elements; the first data line at least includes one sub-data line connected with the first pixel circuit and at least includes another sub-data line connected with the second pixel circuit.

Abstract: The disclosure relates to anti-Siglec-10 antibodies and the use of such antibodies in cancer therapy.

Abstract: The present invention relates to the technical field of blood glucose monitoring, and in particular to a split-type real-time blood glucose monitoring apparatus and a manufacturing method therefor. The real-time blood glucose monitoring apparatus comprises a sensor assembly and an emitter assembly. The sensor assembly comprises a first shell, and a conductive plating, a blood glucose sensor and a battery which are arranged on the first shell. The emitter assembly comprises a second shell and a circuit board in the second shell. The conductive plating is arranged on a shell wall of the first shell and is connected to the blood glucose sensor and the battery, and the conductive plating is provided with at least one first connecting structure; and the circuit board is provided with at least one second connecting structure.

Abstract: The present invention relates to the use of hypoxia-inducible factor (HIF) inhibitors in cancer immunotherapy. Specifically, the disclosure provides methods of treating a cancer in a subject in need of cancer immunotherapy, comprising administering a HIF-1a inhibitor to the subject and a second cancer immunotherapeutic agent to the subject, wherein the HIF-1a inhibitor comprising echinomycin, and wherein the second cancer immunotherapeutic agent comprising an anti-CTLA-4 antibody including Ipilimumab or Tremelimumab.

Abstract: The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.

Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.

Abstract: An insulin pump bolus infusion control method. A control module of a pump body controls the pump body to start a bolus infusion control mode after receiving a function starting signal; in the bolus infusion control mode, a bolus key of a control terminal or a bolus key of an insulin pump body sends an infusion dosage signal to the control module by means of one or more operations; if the control module receives a confirmation signal within a predetermined period of time, then the control module controls the pump body to start bolus infusion; and if the control module receives a cancellation signal or does not receive the confirmation signal within a predetermined period of time, then the control module controls the pump body to exit the bolus infusion mode. Using the method enables an insulin pump to execute a more reasonable control when carrying out the bolus infusion, i.e., starting, setting and implementation of the bolus infusion, and enables a simple and quick operation.

Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.

Abstract: Provided is the use of a CD24 protein for treating viral pneumonia.

Abstract: Provided is the use of a CD24 protein for treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Abstract: The present invention relates to the use of a CD24 protein for treating Systemic Lupus Erythematosus (Lupus, SLE).

Abstract: The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.

Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.

Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.

Abstract: The present invention relates to the use of a CD24 protein for treating Systemic Lupus Erythematosus (Lupus, SLE).

Abstract: The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders

Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.

Abstract: Provided herein are methods and compositions for lowering low-density lipoprotein cholesterol or glucose levels, and for treating subjects with prediabetes or diabetes by targeting CD24-Siglec interactions.